SABS News and Press, SAB Biotherapeutics Inc. From 05/12/22

Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel platform Phase 2 data for SAB-185 expected to be available later this year Sufficient cash anticipated to oper...

SIOUX FALLS, S.D., May 12, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), announced today its participation at the H.C. Wainwright Global Investment Conference , which takes place May 23-26, 2022. As part of the conference, the company’s management team will partici...

Gainers: Sunshine Biopharma (SBFM) +132%. Dingdong Limited (DDL) +29%. System1 (SST) +27%. FG Financial Group (FGF) +25%. Missfresh (MF) +21%. BT Brands (BTBD) +20%. Longeveron (LGVN) +18%. Compass Therapeutics (CMPX) +18%. Allego (ALLG) +17%. Nam Tai Property (NTP) +15%. Losers: IMARA (IMRA)...

SIOUX FALLS, S.D., April 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for...

SELLAS Life Sciences SLS -39% plunged 24% on $25M stock offering. ARCA biopharma ABIO -22% fails to meet key goal in mid-stage trial for COVID-19 therapy. Redwire RDW -18% on Q4 results. Blend Labs BLND -18% on Q4 results. Nuvve Holding NVVE -15% o...

Gainers: Longeveron (LGVN) +62%. Clovis Oncology (CLVS) +61%. Icosavax (ICVX) +26%. Integrated Media Technology (IMTE) +28%. SAB Biotherapeutics (SABS) +21%. Local Bounti (LOCL) +21%. CPS Technologies (CPSH) +18%. Vector Group (VGR) +17%. Nano-X Imaging (NNOX) +16%. Vertex Energy (VTNR) +16%....

SAB Biotherapeutics press release (SABS): FY GAAP EPS of -$0.63.  Cash and cash equivalents were $33.2M as of December 31, 2021, as compared to $12.6M as of December 31, 2020. For further details see: SAB Biotherapeutics GAAP EPS of -$0.63

SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised patients Plans to announce full data from Phase 2a trial that evaluated SAB-176 for the treatment of seasonal inf...

RIGL announced Q4'21 earnings in early March leading the stock to rally over 20%. RIGL's net product sales were as expected and are actually a little flat looking quarter-by-quarter. RIGL's progress in the COVID-19 trial is a bright spot, and a likely driver behind the run the sto...

SAB Biotherapeutics (NASDAQ:SABS) said the National Institutes of Health (NIH) is closing enrollment in its ACTIV-2 trial due to low Omicron-related COVID-19 hospitalization and death rates that have made the current study design statistically unworkable. SAB-185 was being evaluated as part o...